140 related articles for article (PubMed ID: 38064969)
1. Promising applications of nanotechnology in inhibiting chemo-resistance in solid tumors by targeting epithelial-mesenchymal transition (EMT).
Tangsiri M; Hheidari A; Liaghat M; Razlansari M; Ebrahimi N; Akbari A; Varnosfaderani SMN; Maleki-Sheikhabadi F; Norouzi A; Bakhtiyari M; Zalpoor H; Nabi-Afjadi M; Rahdar A
Biomed Pharmacother; 2024 Jan; 170():115973. PubMed ID: 38064969
[TBL] [Abstract][Full Text] [Related]
2. miR-200b regulates epithelial-mesenchymal transition of chemo-resistant breast cancer cells by targeting FN1.
Yang X; Hu Q; Hu LX; Lin XR; Liu JQ; Lin X; Dinglin XX; Zeng JY; Hu H; Luo ML; Yao HR
Discov Med; 2017 Sep; 24(131):75-85. PubMed ID: 28972876
[TBL] [Abstract][Full Text] [Related]
3. Identification of biomarkers associated with partial epithelial to mesenchymal transition in the secretome of slug over-expressing hepatocellular carcinoma cells.
Karaosmanoğlu O; Banerjee S; Sivas H
Cell Oncol (Dordr); 2018 Aug; 41(4):439-453. PubMed ID: 29858962
[TBL] [Abstract][Full Text] [Related]
4. MiR-203 downregulation is responsible for chemoresistance in human glioblastoma by promoting epithelial-mesenchymal transition via SNAI2.
Liao H; Bai Y; Qiu S; Zheng L; Huang L; Liu T; Wang X; Liu Y; Xu N; Yan X; Guo H
Oncotarget; 2015 Apr; 6(11):8914-28. PubMed ID: 25871397
[TBL] [Abstract][Full Text] [Related]
5. Resveratrol reverses Doxorubicin resistance by inhibiting epithelial-mesenchymal transition (EMT) through modulating PTEN/Akt signaling pathway in gastric cancer.
Xu J; Liu D; Niu H; Zhu G; Xu Y; Ye D; Li J; Zhang Q
J Exp Clin Cancer Res; 2017 Jan; 36(1):19. PubMed ID: 28126034
[TBL] [Abstract][Full Text] [Related]
6. FGFR signaling maintains a drug persistent cell population following epithelial-mesenchymal transition.
Brown WS; Akhand SS; Wendt MK
Oncotarget; 2016 Dec; 7(50):83424-83436. PubMed ID: 27825137
[TBL] [Abstract][Full Text] [Related]
7. Critical contribution of MCL-1 in EMT-associated chemo-resistance in A549 non-small cell lung cancer.
Toge M; Yokoyama S; Kato S; Sakurai H; Senda K; Doki Y; Hayakawa Y; Yoshimura N; Saiki I
Int J Oncol; 2015 Apr; 46(4):1844-8. PubMed ID: 25647738
[TBL] [Abstract][Full Text] [Related]
8. Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial-mesenchymal transition interlinked with reprogrammed metabolism.
Leung D; Price ZK; Lokman NA; Wang W; Goonetilleke L; Kadife E; Oehler MK; Ricciardelli C; Kannourakis G; Ahmed N
J Transl Med; 2022 Dec; 20(1):556. PubMed ID: 36463238
[TBL] [Abstract][Full Text] [Related]
9. Targeting EMT in Cancer with Repurposed Metabolic Inhibitors.
Ramesh V; Brabletz T; Ceppi P
Trends Cancer; 2020 Nov; 6(11):942-950. PubMed ID: 32680650
[TBL] [Abstract][Full Text] [Related]
10. Nicastrin and Notch4 drive endocrine therapy resistance and epithelial to mesenchymal transition in MCF7 breast cancer cells.
Lombardo Y; Faronato M; Filipovic A; Vircillo V; Magnani L; Coombes RC
Breast Cancer Res; 2014 Jun; 16(3):R62. PubMed ID: 24919951
[TBL] [Abstract][Full Text] [Related]
11. Catechol enhances chemo‑ and radio‑sensitivity by targeting AMPK/Hippo signaling in pancreatic cancer cells.
Moon JY; Ediriweera MK; Ryu JY; Kim HY; Cho SK
Oncol Rep; 2021 Mar; 45(3):1133-1141. PubMed ID: 33650657
[TBL] [Abstract][Full Text] [Related]
12. Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer.
Du B; Shim JS
Molecules; 2016 Jul; 21(7):. PubMed ID: 27455225
[TBL] [Abstract][Full Text] [Related]
13. Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients.
Tan TZ; Miow QH; Miki Y; Noda T; Mori S; Huang RY; Thiery JP
EMBO Mol Med; 2014 Oct; 6(10):1279-93. PubMed ID: 25214461
[TBL] [Abstract][Full Text] [Related]
14. Reversal of epithelial-mesenchymal transition and inhibition of tumor stemness of breast cancer cells through advanced combined chemotherapy.
Cui Y; Zhao M; Yang Y; Xu R; Tong L; Liang J; Zhang X; Sun Y; Fan Y
Acta Biomater; 2022 Oct; 152():380-392. PubMed ID: 36028199
[TBL] [Abstract][Full Text] [Related]
15. Notch1 Affects Chemo-resistance Through Regulating Epithelial-Mesenchymal Transition (EMT) in Epithelial Ovarian cancer cells.
Qian XQ; Tang SS; Shen YM; Chen LL; Cheng XD; Wan XY
Int J Med Sci; 2020; 17(9):1215-1223. PubMed ID: 32547317
[No Abstract] [Full Text] [Related]
16. Breast cancer cells: Focus on the consequences of epithelial-to-mesenchymal transition.
Bong AHL; Monteith GR
Int J Biochem Cell Biol; 2017 Jun; 87():23-26. PubMed ID: 28336365
[TBL] [Abstract][Full Text] [Related]
17. Targeting lipid metabolism to overcome EMT-associated drug resistance via integrin β3/FAK pathway and tumor-associated macrophage repolarization using legumain-activatable delivery.
Jin H; He Y; Zhao P; Hu Y; Tao J; Chen J; Huang Y
Theranostics; 2019; 9(1):265-278. PubMed ID: 30662566
[TBL] [Abstract][Full Text] [Related]
18. DNA methylation-driven EMT is a common mechanism of resistance to various therapeutic agents in cancer.
Galle E; Thienpont B; Cappuyns S; Venken T; Busschaert P; Van Haele M; Van Cutsem E; Roskams T; van Pelt J; Verslype C; Dekervel J; Lambrechts D
Clin Epigenetics; 2020 Feb; 12(1):27. PubMed ID: 32059745
[TBL] [Abstract][Full Text] [Related]
19. The network of epithelial-mesenchymal transition: potential new targets for tumor resistance.
Nantajit D; Lin D; Li JJ
J Cancer Res Clin Oncol; 2015 Oct; 141(10):1697-713. PubMed ID: 25270087
[TBL] [Abstract][Full Text] [Related]
20. Epithelial to mesenchymal transition (EMT) in metaplastic breast cancer and phyllodes breast tumors.
Akrida I; Mulita F; Plachouri KM; Benetatos N; Maroulis I; Papadaki H
Med Oncol; 2023 Dec; 41(1):20. PubMed ID: 38104042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
